Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors

Research output: Contribution to journalArticle

Abstract

The small subpopulation of breast cancer cells that possess the capability for self-renewal and formation of secondary tumours that recapitulate the heterogeneity of the primary tumour are referred to as tumour-initiating cells or BCSCs (breast cancer stem cells). The hypoxic tumour microenvironment and chemotherapy actively induce the BCSC phenotype. HIFs (hypoxia-inducible factors) are required and molecular mechanisms by which they promote the BCSC phenotype have recently been delineated. HIF inhibitors block chemotherapy-induced enrichment of BCSCs, suggesting that their use may improve the response to chemotherapy and increase the survival of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)1037-1045
Number of pages9
JournalClinical Science
Volume129
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Cell Hypoxia
Neoplastic Stem Cells
Breast Neoplasms
Phenotype
Drug Therapy
Tumor Microenvironment
Neoplasms
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors. / Semenza, Gregg L.

In: Clinical Science, Vol. 129, No. 12, 2015, p. 1037-1045.

Research output: Contribution to journalArticle

@article{8c3d089119a943029ad9425c0f4e95eb,
title = "Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors",
abstract = "The small subpopulation of breast cancer cells that possess the capability for self-renewal and formation of secondary tumours that recapitulate the heterogeneity of the primary tumour are referred to as tumour-initiating cells or BCSCs (breast cancer stem cells). The hypoxic tumour microenvironment and chemotherapy actively induce the BCSC phenotype. HIFs (hypoxia-inducible factors) are required and molecular mechanisms by which they promote the BCSC phenotype have recently been delineated. HIF inhibitors block chemotherapy-induced enrichment of BCSCs, suggesting that their use may improve the response to chemotherapy and increase the survival of breast cancer patients.",
author = "Semenza, {Gregg L}",
year = "2015",
doi = "10.1042/CS20150451",
language = "English (US)",
volume = "129",
pages = "1037--1045",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "12",

}

TY - JOUR

T1 - Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors

AU - Semenza, Gregg L

PY - 2015

Y1 - 2015

N2 - The small subpopulation of breast cancer cells that possess the capability for self-renewal and formation of secondary tumours that recapitulate the heterogeneity of the primary tumour are referred to as tumour-initiating cells or BCSCs (breast cancer stem cells). The hypoxic tumour microenvironment and chemotherapy actively induce the BCSC phenotype. HIFs (hypoxia-inducible factors) are required and molecular mechanisms by which they promote the BCSC phenotype have recently been delineated. HIF inhibitors block chemotherapy-induced enrichment of BCSCs, suggesting that their use may improve the response to chemotherapy and increase the survival of breast cancer patients.

AB - The small subpopulation of breast cancer cells that possess the capability for self-renewal and formation of secondary tumours that recapitulate the heterogeneity of the primary tumour are referred to as tumour-initiating cells or BCSCs (breast cancer stem cells). The hypoxic tumour microenvironment and chemotherapy actively induce the BCSC phenotype. HIFs (hypoxia-inducible factors) are required and molecular mechanisms by which they promote the BCSC phenotype have recently been delineated. HIF inhibitors block chemotherapy-induced enrichment of BCSCs, suggesting that their use may improve the response to chemotherapy and increase the survival of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84951993647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951993647&partnerID=8YFLogxK

U2 - 10.1042/CS20150451

DO - 10.1042/CS20150451

M3 - Article

C2 - 26405042

AN - SCOPUS:84951993647

VL - 129

SP - 1037

EP - 1045

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 12

ER -